Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC Objectives To assess the effectiveness and safety of pembrolizumab monotherapy and in combination with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC). Introduction Historically, patients with advanced NSCLC have a poor prognosis despite the use of platinum-based chemotherapy drugs. The 5-year relative survival rate of
Tag: immune checkpoint inhibitors
